Relative Bioavailability of First vs Second-Generation Formulations of HRS9531 Tablets in Obese or Overweight Subjects

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

168

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

February 28, 2026

Study Completion Date

September 30, 2026

Conditions

Overweight or Obesity

Interventions

DRUG

HRS-9531 Tablet

HRS-9531 tablet.

Trial Locations (1)

The Second Affiliated Hospital of Anhui Medical University, Hefei

All Listed Sponsors

lead

Fujian Shengdi Pharmaceutical Co., Ltd.

INDUSTRY